Treatment of type i and II hereditary angioedema with Rhucin ®, a recombinant human C1 inhibitor

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hereditary and acquired angioedema are of outstanding clinical importance, as edematous attacks associated with these conditions can thrust afflicted patients into mortal danger. Currently, C1 inhibitor concentrate - a human blood product - is available as a replacement therapy. In view of the limited number of donors, as well as the risk of transmission of blood-borne infections, it is a reasonable expectation to develop a therapeutic alternative based on recombinant technology, which would eliminate all these shortcomings. Pharming (Leiden, The Netherlands) has developed Rhucin®, a recombinant human C1 inhibitor, as a proprietary product, which is currently being evaluated in Phase III clinical trials. Ongoing studies conducted within the framework of the development program are almost complete and their interim findings are reassuring. This should facilitate successful regulatory approval in the near future, which is indispensable in order to make Rhucin available for patients with hereditary angioedema or other disorders amenable to C1 inhibitor replacement.

Original languageEnglish
Pages (from-to)653-661
Number of pages9
JournalExpert Review of Clinical Immunology
Volume4
Issue number6
DOIs
Publication statusPublished - 2008

Fingerprint

Hereditary Angioedema Types I and II
Hereditary Angioedemas
Phase III Clinical Trials
Netherlands
Tissue Donors
Technology
Therapeutics
Infection
human SERPING1 protein

Keywords

  • Complement
  • Hereditary angioedema
  • Recombinant human C1 inhibitor
  • Rhucin
  • Therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{63ac3360a4454f7f94f47981803ea830,
title = "Treatment of type i and II hereditary angioedema with Rhucin {\circledR}, a recombinant human C1 inhibitor",
abstract = "Hereditary and acquired angioedema are of outstanding clinical importance, as edematous attacks associated with these conditions can thrust afflicted patients into mortal danger. Currently, C1 inhibitor concentrate - a human blood product - is available as a replacement therapy. In view of the limited number of donors, as well as the risk of transmission of blood-borne infections, it is a reasonable expectation to develop a therapeutic alternative based on recombinant technology, which would eliminate all these shortcomings. Pharming (Leiden, The Netherlands) has developed Rhucin{\circledR}, a recombinant human C1 inhibitor, as a proprietary product, which is currently being evaluated in Phase III clinical trials. Ongoing studies conducted within the framework of the development program are almost complete and their interim findings are reassuring. This should facilitate successful regulatory approval in the near future, which is indispensable in order to make Rhucin available for patients with hereditary angioedema or other disorders amenable to C1 inhibitor replacement.",
keywords = "Complement, Hereditary angioedema, Recombinant human C1 inhibitor, Rhucin, Therapy",
author = "L. Varga and H. Farkas",
year = "2008",
doi = "10.1586/1744666X.4.6.653",
language = "English",
volume = "4",
pages = "653--661",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Treatment of type i and II hereditary angioedema with Rhucin ®, a recombinant human C1 inhibitor

AU - Varga, L.

AU - Farkas, H.

PY - 2008

Y1 - 2008

N2 - Hereditary and acquired angioedema are of outstanding clinical importance, as edematous attacks associated with these conditions can thrust afflicted patients into mortal danger. Currently, C1 inhibitor concentrate - a human blood product - is available as a replacement therapy. In view of the limited number of donors, as well as the risk of transmission of blood-borne infections, it is a reasonable expectation to develop a therapeutic alternative based on recombinant technology, which would eliminate all these shortcomings. Pharming (Leiden, The Netherlands) has developed Rhucin®, a recombinant human C1 inhibitor, as a proprietary product, which is currently being evaluated in Phase III clinical trials. Ongoing studies conducted within the framework of the development program are almost complete and their interim findings are reassuring. This should facilitate successful regulatory approval in the near future, which is indispensable in order to make Rhucin available for patients with hereditary angioedema or other disorders amenable to C1 inhibitor replacement.

AB - Hereditary and acquired angioedema are of outstanding clinical importance, as edematous attacks associated with these conditions can thrust afflicted patients into mortal danger. Currently, C1 inhibitor concentrate - a human blood product - is available as a replacement therapy. In view of the limited number of donors, as well as the risk of transmission of blood-borne infections, it is a reasonable expectation to develop a therapeutic alternative based on recombinant technology, which would eliminate all these shortcomings. Pharming (Leiden, The Netherlands) has developed Rhucin®, a recombinant human C1 inhibitor, as a proprietary product, which is currently being evaluated in Phase III clinical trials. Ongoing studies conducted within the framework of the development program are almost complete and their interim findings are reassuring. This should facilitate successful regulatory approval in the near future, which is indispensable in order to make Rhucin available for patients with hereditary angioedema or other disorders amenable to C1 inhibitor replacement.

KW - Complement

KW - Hereditary angioedema

KW - Recombinant human C1 inhibitor

KW - Rhucin

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=77649130357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649130357&partnerID=8YFLogxK

U2 - 10.1586/1744666X.4.6.653

DO - 10.1586/1744666X.4.6.653

M3 - Article

C2 - 20477114

AN - SCOPUS:77649130357

VL - 4

SP - 653

EP - 661

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 6

ER -